← Back to all trials
Recruiting
NCT07096843
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
Conditions: Primary Membranous Nephropathy
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 45
Sponsor: Climb Bio, Inc.
Location: Climb Bio Investigative Site #110 Denver Colorado
Summary
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
Eligibility Criteria
Inclusion Criteria:
* Confirmed diagnosis of PMN with positive anti-PLA2R antibodies
* CD19+ B cell count ≥40 cells/μL
* UPCR ≥2.0 g/g
* eGFR ≥35 mL/min/1.73 m²
* Stable RAAS inhibitor therapy
* Blood pressure \
Source: ClinicalTrials.gov (NCT07096843). StuddyBuddy aggregates publicly available trial information.
